Anssi Auvinen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7719703/publications.pdf

Version: 2024-02-01

496	32,288	4960 84	5679 162
papers	citations	h-index	g-index

510	510	510	28382
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic radiological examinations and risk of intracranial tumours in adultsâ€"findings from the Interphone Study. International Journal of Epidemiology, 2022, 51, 537-546.	1.9	2
2	Associations between systemic medications and development of wet ageâ€related macular degeneration. Acta Ophthalmologica, 2022, 100, 572-582.	1.1	5
3	Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncology, 2022, 8, 61.	7.1	6
4	Sauna habits/bathing and changes in lower urinary tract symptoms â€“ Tampere Ageing Male Urologic Study (TAMUS). Scandinavian Journal of Urology, 2022, 56, 77-82.	1.0	4
5	Populationâ€based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. BJU International, 2022, 130, 193-199.	2.5	13
6	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.4	13
7	Association of allergic diseases and epilepsy with risk of glioma, meningioma and acoustic neuroma: results from the INTERPHONE international caseâ€“control study. European Journal of Epidemiology, 2022, 37, 503-512.	5.7	2
8	Incidence of myelodysplastic syndromes in Finland 1997â€“2016. Leukemia Research, 2022, 116, 106839.	0.8	5
9	Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother. Journal of Urology, 2022, 207, 1285-1294.	0.4	6
10	Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. British Journal of Cancer, 2022, , .	6.4	1
11	Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. Cancers, 2022, 14, 2920.	3.7	3
12	Incidence trends of childhood central nervous system tumors in Finland 1990â€“2017. BMC Cancer, 2022, 22, .	2.6	3
13	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	2.5	15
14	Number of screening rounds attended and incidence of highâ€risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cancer, 2021, 127, 188-192.	4.1	4
15	Seasonal changes in occurrence and severity of lower urinary tract symptomsâ€"Tampere Aging Male Urologic Study (TAMUS). LUTS: Lower Urinary Tract Symptoms, 2021, 13, 216-223.	1.3	1
16	Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers, 2021, 13, 435.	3.7	3
17	Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast Cancer Research and Treatment, 2021, 187, 267-274.	2.5	8
18	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264

#	Article	IF	Citations
19	Impact of cancer screening on metastasis: A prostate cancer case study. Journal of Medical Screening, 2021, 28, 096914132198973.	2.3	0
20	Pharmacoepidemiological Evaluation in Prostate Cancerâ€"Common Pitfalls and How to Avoid Them. Cancers, 2021, 13, 696.	3.7	6
21	Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 982-989.	2.5	3
22	Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. International Journal of Cancer, 2021, 149, 307-315.	5.1	3
23	A cohort study on adult hematological malignancies and brain tumors in relation to magnetic fields from indoor transformer stations. International Journal of Hygiene and Environmental Health, 2021, 233, 113712.	4.3	7
24	Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer and Prostatic Diseases, 2021, 24, 1158-1166.	3.9	5
25	Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer. Cancer Causes and Control, 2021, 32, 1299-1313.	1.8	6
26	Comparability and validity of cancer registry data in the northwest of Russia. Acta OncolÃ³gica, 2021, 60, 1264-1271.	1.8	5
27	Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9â€‰ng/ml: long-term results from a randomized trial. Scandinavian Journal of Urology, 2021, 55, 348-353.	1.0	8
28	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. European Urology Open Science, 2021, 30, 47-62.	0.4	2
29	Methodological considerations for interrupted time series analysis in radiation epidemiology: an overview. Journal of Radiological Protection, 2021, 41, 609-618.	1.1	2
30	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. European Urology Focus, 2021, 7, 943-946.	3.1	6
31	Are There Limits in Explainability of Prognostic Biomarkers? Scrutinizing Biological Utility of Established Signatures. Cancers, 2021, 13, 5087.	3.7	1
32	Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer. European Urology Open Science, 2021, 34, 27-32.	0.4	1
33	Cancer screening simulation models: a state of the art review. BMC Medical Informatics and Decision Making, 2021, 21, 359.	3.0	5
34	Clinical and epidemiological observations on individual radiation sensitivity and susceptibility. International Journal of Radiation Biology, 2020, 96, 324-339.	1.8	35
35	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	5.4	24
36	Epidemiological studies of natural sources of radiation and childhood cancer: current challenges and future perspectives. Journal of Radiological Protection, 2020, 40, R1-R23.	1.1	14

#	Article	IF	Citations
37	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. Cancer Imaging, 2020, 20, 72.	2.8	10
38	Prostate cancer risk prediction using a polygenic risk score. Scientific Reports, 2020, 10, 17075.	3.3	39
39	Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening. Scientific Reports, 2020, 10, 20665.	3.3	1
40	Longâ€term healthâ€related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. Cancer Medicine, 2020, 9, 5643-5654.	2.8	4
41	Age-, sex- and disease subtypeâ€“related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. European Journal of Cancer, 2020, 130, 1-11.	2.8	7
42	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS ONE, 2020, 15, e0234269.	2.5	12
43	Trends and predictors in all-cause and cause-specific mortality in diabetic and reference populations during 21 years of follow-up. Journal of Epidemiology and Community Health, 2020, 74, jech-2019-213602.	3.7	4
44	Long-term effect of mobile phone use on sleep quality: Results from the cohort study of mobile phone use and health (COSMOS). Environment International, 2020, 140, 105687.	10.0	32
45	Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer. European Journal of Cancer, 2020, 130, 204-210.	2.8	6
46	The Impact of Nocturia on Mortality: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 486-495.	0.4	51
47	Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. Scandinavian Journal of Work, Environment and Health, 2020, 46, 278-292.	3.4	12
48	Malignant Tumors of the Central Nervous System. , 2020, , 507-524.		0
49	Trends of computed tomography use among children in Finland. European Journal of Radiology Open, 2020, 7, 100290.	1.6	3
50	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
51	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
52	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
53	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
54	Productivity losses associated with premature mortality due to cancer in Russia: A population-wide study covering 2001â€“2030. Scandinavian Journal of Public Health, 2019, 47, 482-491.	2.3	11

#	Article	IF	Citations
55	Headache, tinnitus and hearing loss in the international Cohort Study of Mobile Phone Use and Health (COSMOS) in Sweden and Finland. International Journal of Epidemiology, 2019, 48, 1567-1579.	1.9	33
56	Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer. Cancer Causes and Control, 2019, 30, 877-888.	1.8	5
57	Parental occupational exposure to low-frequency magnetic fields and risk of leukaemia in the offspring: findings from the Childhood Leukaemia International Consortium (CLIC). Occupational and Environmental Medicine, 2019, 76, 746-753.	2.8	10
58	Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time . Clinical Epidemiology, 2019, Volume 11, 923-932.	3.0	37
59	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	1.9	18
60	Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 453-460.	3.9	11
61	Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Prostate Cancer and Prostatic Diseases, 2019, 22, 483-490.	3.9	6
62	Fertility and marital status in adults with childhood onset epilepsy: A populationâ€based cohort study. Epilepsia, 2019, 60, 1438-1444.	5.1	4
63	Incidence trends of adult malignant brain tumors in Finland, 1990â€“2016. Acta OncolÃ³gica, 2019, 58, 990-996.	1.8	11
64	The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers. European Urology, 2019, 76, 276-279.	1.9	8
65	Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. European Urology, 2019, 75, 1015-1022.	1.9	7
66	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 2019, 76, 43-51.	1.9	359
67	Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. Cancer Epidemiology, 2019, 59, 158-165.	1.9	23
68	Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. PLoS ONE, 2019, 14, e0224479.	2.5	6
69	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
70	Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 66-76.	3.9	28
71	Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden. Journal of Neuro-Oncology, 2019, 141, 139-149.	2.9	8
72	Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer and Prostatic Diseases, 2019, 22, 317-323.	3.9	11

#	Article	IF	Citations
73	Biasâ€corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. International Journal of Cancer, 2019, 145, 632-638.	5.1	3
74	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
75	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clinical Cancer Research, 2019, 25, 839-843.	7.0	7
76	OBSOLETE: Cancer Screening: Theory and Applications. , 2019, , .		0
77	Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. European Urology Focus, 2019, 5, 186-191.	3.1	3
78	A Four-kallikrein Panel and Î²-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. European Urology Focus, 2019, 5, 561-567.	3.1	8
79	Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. Journal of Urology, 2019, 201, 486-495.	0.4	28
80	Exposure to loud noise and risk of vestibular schwannoma: results from the INTERPHONE international caseâ€'control study. Scandinavian Journal of Work, Environment and Health, 2019, 45, 183-193.	3.4	4
81	Spatio-Temporal Clustering of Childhood Leukemia Relative to Population Mixing in Finland: A Nationwide Register-Based Study. Blood, 2019, 134, 5070-5070.	1.4	0
82	Title is missing!. , 2019, 14, e0224479.		0
83	Title is missing!. , 2019, 14, e0224479.		0
84	Title is missing!. , 2019, 14, e0224479.		0
85	Title is missing!. , 2019, 14, e0224479.		0
86	Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. British Journal of Cancer, 2018, 118, 1248-1254.	6.4	18
87	Multidisciplinary European Low Dose Initiative (MELODI): strategic research agenda for low dose radiation risk research. Radiation and Environmental Biophysics, 2018, 57, 5-15.	1.4	44
88	Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer and Prostatic Diseases, 2018, 21, 373-378.	3.9	7
89	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 2018, 121, 737-744.	2.5	51
90	Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. European Journal of Cancer, 2018, 93, 108-118.	2.8	4

#	Article	IF	Citations
91	Bayesian negative-binomial-family-based multistate Markov model for the evaluation of periodic population-based cancer screening considering incomplete information and measurement errors. Statistical Methods in Medical Research, 2018, 27, 2519-2539.	1.5	2
92	Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. European Urology Focus, 2018, 4, 851-857.	3.1	5
93	An international prospective cohort study of mobile phone users and health (COSMOS): Factors affecting validity of self-reported mobile phone use. International Journal of Hygiene and Environmental Health, 2018, 221, 1-8.	4.3	14
94	Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. International Journal of Urology, 2018, 25, 270-276.	1.0	11
95	The efficacy of prostateâ€specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer, 2018, 124, 1197-1206.	4.1	56
96	Prostate cancer screening: what can we learn from randomised trials?. Translational Andrology and Urology, 2018, 7, 12-17.	1.4	2
97	Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scandinavian Journal of Urology, 2018, 52, 321-327.	1.0	9
98	Severity and bother of lower urinary tract symptoms among men aged 30â€“80Âyears: Tampere Ageing Male Urological Study (TAMUS). Scandinavian Journal of Urology, 2018, 52, 296-301.	1.0	1
99	Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC. Lancet Oncology, The, 2018, 19, 1280-1283.	10.7	23
100	Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer. Clinical Cancer Research, 2018, 24, 6265-6276.	7.0	17
101	Breast and cervical cancer incidence and mortality trends in Russia 1980â€“2013. Cancer Epidemiology, 2018, 55, 73-80.	1.9	32
102	Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. European Journal of Epidemiology, 2018, 33, 965-976.	5.7	44
103	Effects of incomplete residential histories on studies of environmental exposure with application to childhood leukaemia and background radiation. Environmental Research, 2018, 166, 466-472.	7.5	14
104	Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. Scientific Reports, 2018, 8, 10308.	3.3	2
105	Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). Haematologica, 2018, 103, 1873-1880.	3.5	30
106	Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell, 2018, 174, 576-589.e18.	28.9	116
107	Cardiovascular Morbidity and Mortality After Treatment of Hyperthyroidism with Either Radioactive Iodine or Thyroidectomy. Thyroid, 2018, 28, 1111-1120.	4.5	40
108	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652

#	Article	IF	Citations
109	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
110	Abstract 4226: Association between NSAID, statins, and bisphosphonates and prostate cancer survival during androgen deprivation therapy. , 2018, , .		1
111	Excess mortality in Finnish diabetic subjects due to alcohol, accidents and suicide: a nationwide study. European Journal of Endocrinology, 2018, 179, 299-306.	3.7	9
112	What explains the differences between centres in the European screening trial? A simulation study. Cancer Epidemiology, 2017, 46, 14-19.	1.9	3
113	Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. Journal of Urology, 2017, 198, 50-57.	0.4	24
114	Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian Journal of Urology, 2017, 51, 5-12.	1.0	41
115	Outcomes of Prostate Cancer Screening by 5Î±-Reductase Inhibitor Use. Journal of Urology, 2017, 198, 305-309.	0.4	3
116	Women treated for epilepsy during pregnancy: outcomes from a nationwide populationâ€based cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 812-820.	2.8	22
117	Estimation of occupational cosmic radiation exposure among airline personnel: Agreement between a jobâ€exposure matrix, aggregate, and individual dose estimates. American Journal of Industrial Medicine, 2017, 60, 386-393.	2.1	4
118	The effect of nonâ€steroidal antiâ€inflammatory drugs on risk of benign prostatic hyperplasia. Prostate, 2017, 77, 1029-1035.	2.3	8
119	Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia, 2017, 60, 1691-1703.	6.3	57
120	Occupational solvent exposure and adult chronic lymphocytic leukemia: No risk in a population-based case-control study in four Nordic countries. International Journal of Cancer, 2017, 141, 1140-1147.	5.1	14
121	Risk of Causeâ€Specific Death in Individuals with Cancerâ€”Modifying Role Diabetes, Statins and Metformin. International Journal of Cancer, 2017, 141, 2437-2449.	5.1	23
122	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2017, 167, 449.	3.9	160
123	PD40-06 A FOUR-KALLIKREIN PANEL IN PREDICTING HIGH-GRADE PROSTATE CANCER ON BIOPSY: AN INDEPENDENT REPLICATION FROM THE FINNISH SECTION OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER.. Journal of Urology, 2017, 197, .	0.4	0
124	PD40-03 EFFECT OF 5-ALFA REDUCTASE INHIBITOR USAGE ON OUTCOMES OF PROSTATE CANCER SCREENING. Journal of Urology, 2017, 197, .	0.4	0
125	PD47-02 FASTING BLOOD GLUCOSE AND PROSTATE CANCER RISK IN THE FINNISH RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	0
126	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. European Journal of Epidemiology, 2017, 32, 521-527.	5.7	36

#	Article	IF	Citations
127	Costs of Robotic-Assisted Versus Traditional Laparoscopy in Endometrial Cancer. International Journal of Gynecological Cancer, 2017, 27, 1788-1793.	2.5	8
128	Impact of cause of death adjudication on the results of the European prostate cancer screening trial. British Journal of Cancer, 2017, 116, 141-148.	6.4	11
129	National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis. World Journal of Urology, 2017, 35, 851-858.	2.2	21
130	Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. European Urology Focus, 2017, 3, 212-220.	3.1	37
131	Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. BMC Cancer, 2017, 17, 585.	2.6	9
132	Diabetes and Breast Cancer Subtypes. PLoS ONE, 2017, 12, e0170084.	2.5	47
133	Cancer Screening: Theory and Applications. , 2017, , 389-405.		1
134	Abstract 3290: Cancer mortality by antiarrhythmic drug use in a population-based cohort of Finnish men. , 2017, , .		0
135	5â€Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. International Journal of Cancer, 2016, 138, 2820-2828.	5.1	14
136	Prudent practice optimizes screening outcomes. Nature Reviews Urology, 2016, 13, 376-377.	3.8	0
137	PD09-04 ESTIMATING THE HARMS AND BENEFITS OF PROSTATE CANCER SCREENING: COMPARING COMMON CLINICAL PRACTICE TO RECOMMENDED GOOD PRACTICE. Journal of Urology, 2016, 195, .	0.4	0
138	PD09-01 CORRELATION BETWEEN STAGE SHIFT AND DIFFERENCES IN MORTALITY BETWEEN THE TWO STUDY ARMS OF THE ERSPC.. Journal of Urology, 2016, 195, .	0.4	0
139	Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based caseâ€“control study. Cancer Causes and Control, 2016, 27, 637-645.	1.8	13
140	Insulin glargine use and breast cancer risk: Associations with cumulative exposure. Acta OncolÃ³gica, 2016, 55, 851-858.	1.8	14
141	Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men. Urology, 2016, 95, 164-170.	1.0	6
142	Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. European Urology, 2016, 70, 499-505.	1.9	6
143	Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC). BJU International, 2016, 118, 677-680.	2.5	9
144	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer, 2016, 122, 3386-3393.	4.1	23

#	Article	IF	Citations
145	Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer. Cancer Epidemiology, 2016, 45, 1-5.	1.9	14
146	Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian Journal of Urology, 2016, 50, 413-419.	1.0	14
147	Background radiation and childhood leukemia: A nationwide registerâ€based caseâ€control study. International Journal of Cancer, 2016, 139, 1975-1982.	5.1	37
148	The Intracranial Distribution of Gliomas in Relation to Exposure From Mobile Phones: Analyses From the INTERPHONE Study. American Journal of Epidemiology, 2016, 184, 818-828.	3.4	21
149	Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. British Journal of Cancer, 2016, 115, 1289-1295.	6.4	12
150	Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer. American Journal of Epidemiology, 2016, 184, 720-731.	3.4	36
151	Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis. European Urology, 2016, 70, 372-381.	1.9	20
152	Residential mobility and the risk of childhood leukemia. Cancer Causes and Control, 2016, 27, 433-443.	1.8	6
153	Incidence of Pediatric Inflammatory Bowel Disease in Finland. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 65-70.	1.8	10
154	Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial. Cancer Causes and Control, 2016, 27, 157-164.	1.8	11
155	Re. Epidemiology, 2016, 27, e20-e21.	2.7	23
156	Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. Scandinavian Journal of Urology, 2016, 50, 267-273.	1.0	30
157	Epilepsy, excess deaths and years of life lost from external causes. European Journal of Epidemiology, 2016, 31, 445-453.	5.7	21
158	Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. Clinical Cancer Research, 2016, 22, 243-249.	7.0	35
159	Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. PLoS ONE, 2016, 11, e0153413.	2.5	18
160	PD6-02 5-ALPHA REDUCTASE INHIBITOR USE AND PROSTATE CANCER SURVIVAL IN THE FINNISH PROSTATE CANCER SCREENING TRIAL. Journal of Urology, 2015, 193, .	0.4	0
161	PD6-09 POLYMORPHISMS IN GENES OF THE GLUCOSE- AND ENERGY-METABOLISM PATHWAYS AND PROSTATE CANCER: INTERPLAY WITH METFORMIN. Journal of Urology, 2015, 193, .	0.4	0
162	The Finnish prostate cancer screening trial: Analyses on the screening failures. International Journal of Cancer, 2015, 136, 2437-2443.	5.1	11

#	Article	IF	Citations
163	Family history in the <scp>F</scp>innish <scp>P</scp>rostate <scp>C</scp>ancer <scp>S</scp>creening <scp>T</scp>rial. International Journal of Cancer, 2015, 136, 2172-2177.	5.1	20
164	Chernobyl cleanup workers from Estonia: cohort description and related epidemiological research. Journal of Radiological Protection, 2015, 35, R35-R45.	1.1	9
165	Prostate cancer screening using risk stratification based on a multiâ€state model of genetic variants. Prostate, 2015, 75, 825-835.	2.3	2
166	Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial. Prostate, 2015, 75, 1394-1402.	2.3	19
167	Eye Lens Opacities Among Physicians Occupationally Exposed to Ionizing Radiation. Annals of Occupational Hygiene, 2015, 59, 945-948.	1.9	13
168	Sotalol, but not digoxin is associated with decreased prostate cancer risk: A populationâ€based caseâ€“control study. International Journal of Cancer, 2015, 137, 1187-1195.	5.1	21
169	Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. Journal of the National Cancer Institute, 2015, 107, 366.	6.3	120
170	European Code against Cancer 4th Edition: Ionising and non-ionising radiation and cancer. Cancer Epidemiology, 2015, 39, S93-S100.	1.9	44
171	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	1.9	176
172	European Code against Cancer 4th Edition: Ultraviolet radiation and cancer. Cancer Epidemiology, 2015, 39, S75-S83.	1.9	83
173	Pituitary tumor risk in relation to mobile phone use: A case-control study. Acta OncolÃ³gica, 2015, 54, 1159-1165.	1.8	7
174	Prostate cancer screening in Europe â€“ Authors' reply. Lancet, The, 2015, 385, 1507-1508.	13.7	4
175	Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. European Urology, 2015, 68, 885-890.	1.9	111
176	Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. European Urology, 2015, 68, 1089-1097.	1.9	7
177	Low-dose ionising radiation and cardiovascular diseases â€“ Strategies for molecular epidemiological studies in Europe. Mutation Research - Reviews in Mutation Research, 2015, 764, 90-100.	5.5	64
178	European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. Cancer Epidemiology, 2015, 39, S107-S119.	1.9	35
179	Population attitudes towards research use of health care registries: a population-based survey in Finland. BMC Medical Ethics, 2015, 16, 48.	2.4	13
180	Cancer Incidence and Mortality in Patients Treated Either With RAI or Thyroidectomy for Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3710-3717.	3.6	43

#	Article	IF	Citations
181	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. British Journal of Cancer, 2015, 113, 1086-1093.	6.4	32
182	Application of the ELDO approach to assess cumulative eye lens doses for interventional cardiologists. Radiation Protection Dosimetry, 2015, 164, 84-88.	0.8	12
183	Abstract 4681: Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish arm of the European randomised study of screening for prostate cancer (ERSPC). , 2015, , .		0
184	Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis. PLoS ONE, 2014, 9, e89508.	2.5	7
185	A Framework for Estimating Radiation-Related Cancer Risks in Japan from the 2011 Fukushima Nuclear Accident. Radiation Research, 2014, 182, 556.	1.5	23
186	Chernobyl fallout and cancer incidence in Finland 1988â€“2007. International Journal of Cancer, 2014, 134, 2253-2263.	5.1	13
187	Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. British Journal of Cancer, 2014, 111, 1421-1431.	6.4	26
188	Cardiovascular morbidity and mortality in surgically treated hyperthyroidism â€“ a nationâ€wide cohort study with a longâ€term followâ€up. Clinical Endocrinology, 2014, 80, 743-750.	2.4	26
189	Outcomes of medical and surgical treatment for lower urinary tract symptoms (benign prostatic) Tj ETQq1 1 0.784314 rgBT /Overloc 349-355.	1.7	1
190	Epilepsy-related clinical characteristics and mortality. Neurology, 2014, 83, 1968-1977.	1.1	131
191	RE: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection. Journal of the National Cancer Institute, 2014, 106, .	6.3	4
192	Childhood leukaemia risks: from unexplained findings near nuclear installations to recommendations for future research. Journal of Radiological Protection, 2014, 34, R53-R68.	1.1	13
193	Effect of intervention on decision making of treatment for disease progression, prostateâ€specific antigen biochemical failure and prostate cancer death. Health Expectations, 2014, 17, 776-783.	2.6	2
194	What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women. European Urology, 2014, 65, 1211-1217.	1.9	193
195	Natural Course of Lower Urinary Tract Symptoms in Men Not Requiring TreatmentÂâ€“ÂA 5-Year Longitudinal Population-based Study. Urology, 2014, 83, 411-415.	1.0	7
196	PD31-03 STATIN USE AND SURVIVAL AFTER PROSTATE CANCER DIAGNOSIS IN THE FINNISH PROSTATE CANCER SCREENING TRIAL. Journal of Urology, 2014, 191, .	0.4	1
197	Mortality from cancer and other causes in commercial airline crews: a joint analysis of cohorts from 10 countries. Occupational and Environmental Medicine, 2014, 71, 313-322.	2.8	68
198	Risks from CT scansâ€”what do recent studies tell us?. Journal of Radiological Protection, 2014, 34, E1.	1.1	95

#	Article	IF	Citations
199	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, The, 2014, 384, 2027-2035.	13.7	1,261
200	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
201	Autoimmunity-related immunological serum markers and survival in a tertiary care cohort of adult patients with epilepsy. Epilepsy Research, 2014, 108, 1675-1679.	1.6	4
202	Health-Related Quality of Life in the Finnish Trial of Screening for Prostate Cancer. European Urology, 2014, 65, 39-47.	1.9	21
203	A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality. European Urology, 2014, 66, 401-403.	1.9	14
204	Non-cancer morbidity among Estonian Chernobyl cleanup workers: a register-based cohort study. BMJ Open, 2014, 4, e004516.	1.9	19
205	Malignant Tumors of the Central Nervous System. , 2014, , 481-495.		0
206	Impact of Obesity on Urinary Storage Symptoms: Results from the FINNO Study. Journal of Urology, 2013, 189, 1377-1382.	0.4	31
207	Long-term mortality risk by cause of death in newly diagnosed patients with epilepsy in Finland: a nationwide register-based study. European Journal of Epidemiology, 2013, 28, 981-990.	5.7	36
208	Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death. European Journal of Cancer, 2013, 49, 3335-3343.	2.8	5
209	State of the art in research into the risk of low dose radiation exposureâ€"findings of the fourth MELODI workshop. Journal of Radiological Protection, 2013, 33, 589-603.	1.1	10
210	Fallout from the Chernobyl accident and overall cancer incidence in Finland. Cancer Epidemiology, 2013, 37, 585-592.	1.9	8
211	Site-specific cancer risk in the Baltic cohort of Chernobyl cleanup workers, 1986â€"2007. European Journal of Cancer, 2013, 49, 2926-2933.	2.8	27
212	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
213	Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. European Journal of Cancer, 2013, 49, 938-945.	2.8	65
214	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118
215	Chernobyl cleanup workers from Estonia: follow-up for cancer incidence and mortality. Journal of Radiological Protection, 2013, 33, 395-411.	1.1	22
216	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	2.3	18

#	Article	IF	Citations
217	Prostate Cancer Mortality in the Finnish Randomized Screening Trial. Journal of the National Cancer Institute, 2013, 105, 719-725.	6.3	94
218	Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC). Acta OncolÃ³gica, 2013, 52, 1615-1621.	1.8	20
219	Risk Factors for Skin Cancer among Finnish Airline Cabin Crew. Annals of Occupational Hygiene, 2013, 57, 695-704.	1.9	8
220	HOXB13 G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 452-460.	2.5	75
221	Excess all-cause mortality in the evaluation of a screening trial to account for selective participation. Journal of Medical Screening, 2013, 20, 39-45.	2.3	11
222	A correlation study of eye lens dose and personal dose equivalent for interventional cardiologists. Radiation Protection Dosimetry, 2013, 157, 561-569.	0.8	62
223	Empirical evaluation of grouping of lower urinary tract symptoms: principal component analysis of Tampere Ageing Male Urological Study data. BJU International, 2013, 111, 467-473.	2.5	9
224	Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostateâ€specific antigen (<scp>PSA</scp>) concentration in the <scp>F</scp>innish prostate cancer screening trial. BJU International, 2013, 112, 735-741.	2.5	56
225	CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis. Current Drug Safety, 2013, 8, 296-332.	0.6	52
226	Use of Insulin and Insulin Analogs and Risk of Cancer â€" Systematic Review and Meta-Analysis of Observational Studies. Current Drug Safety, 2013, 8, 333-348.	0.6	95
227	Smoking Cessation Intervention in Rural Kerala, India: Findings of a Randomised Controlled Trial. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6797-6802.	1.2	26
228	Multiple Approaches and Participation Rate for a Community Based Smoking Cessation Intervention Trial in Rural Kerala, India. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2891-2896.	1.2	12
229	TU-A-116-10: Dosimetry Approach for a Retrospective Epidemiological Study On Eye Lens Dose to Interventional Cardiologists and the Occurrence of Radiation-Induced Lens Opacities. Medical Physics, 2013, 40, 428-428.	3.0	0
230	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	2.3	8
231	A Nationwide Cohort Study on the Incidence of Meningioma in Women Using Postmenopausal Hormone Therapy in Finland. American Journal of Epidemiology, 2012, 175, 309-314.	3.4	33
232	Mobile Phone Use and Incidence of Glioma in the Nordic Countries 1979â€"2008. Epidemiology, 2012, 23, 301-307.	2.7	100
233	Association of Repeated Exposure to Antibiotics With the Development of Pediatric Crohn's Disease--A Nationwide, Register-based Finnish Case-Control Study. American Journal of Epidemiology, 2012, 175, 775-784.	3.4	158
234	Quality-of-Life Effects of Prostate-Specific Antigen Screening. New England Journal of Medicine, 2012, 367, 595-605.	27.0	364

#	Article	IF	Citations
235	Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). European Urology, 2012, 62, 745-752.	1.9	216
236	Prevalence and bother of postmicturition dribble in Finnish men aged 30â€“80 years: Tampere Ageing Male Urologic Study (TAMUS). Scandinavian Journal of Urology and Nephrology, 2012, 46, 418-423.	1.4	11
237	Panel discussion does not improve reliability of peer review for medical research grant proposals. Journal of Clinical Epidemiology, 2012, 65, 47-52.	5.0	66
238	Health coaching by telephony to support self-care in chronic diseases: clinical outcomes from The TERVA randomized controlled trial. BMC Health Services Research, 2012, 12, 147.	2.2	43
239	Mortality by clinical characteristics in a tertiary care cohort of adult patients with chronic epilepsy. Epilepsia, 2012, 53, e212-4.	5.1	39
240	Prostate-Cancer Mortality at 11 Years of Follow-up. New England Journal of Medicine, 2012, 366, 981-990.	27.0	1,105
241	Loss of SUFU Function in Familial Multiple Meningioma. American Journal of Human Genetics, 2012, 91, 520-526.	6.2	137
242	Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. International Journal of Cancer, 2012, 131, 1367-1375.	5.1	17
243	Cancer incidence among Nordic airline cabin crew. International Journal of Cancer, 2012, 131, 2886-2897.	5.1	52
244	Systematic review of wireless phone use and brain cancer and other head tumors. Bioelectromagnetics, 2012, 33, 187-206.	1.6	80
245	Does the Imprecise Definition of Overactive Bladder Serve Commercial Rather than Patient Interests?. European Urology, 2012, 61, 746-748.	1.9	19
246	The Impact of Interscreening Interval and Age on Prostate Cancer Screening With Prostate-Specific Antigen. European Urology, 2012, 61, 1011-1018.	1.9	17
247	Prevalence of hesitancy in 30â€“80â€yearâ€old Finnish men: Tampere Ageing Male Urological Study (TAMUS). BJU International, 2012, 109, 1360-1364.	2.5	8
248	A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and overâ€detection. Biometrical Journal, 2012, 54, 20-44.	1.0	14
249	1955 WHAT IS THE MOST BOTHERSOME LOWER URINARY TRACT SYMPTOM? INDIVIDUAL AND POPULATION LEVEL PERSPECTIVES. Journal of Urology, 2011, 185, .	0.4	0
250	25 THE SCREENING TEST NEGATIVE INTERVAL CANCERS CAUSE MORE MORTALITY THAN THE SCREENING TEST POSITIVES. European Urology Supplements, 2011, 10, 36-37.	0.1	0
251	False-positive screening results in the European randomized study of screening for prostate cancer. European Journal of Cancer, 2011, 47, 2698-2705.	2.8	55
252	Number needed to screenâ€”How can we project outside context?. Journal of Clinical Epidemiology, 2011, 64, 1275-1276.	5.0	1

#	Article	IF	Citations
253	Smoking and Bladder Symptoms in Women. Obstetrics and Gynecology, 2011, 118, 643-648.	2.4	44
254	No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU International, 2011, 107, 1912-1917.	2.5	29
255	The Prevalence of Clinically Meaningful Overactive Bladder: Bother and Quality of Life Results from the Population-Based FINNO Study. European Urology, 2011, 59, 629-636.	1.9	88
256	The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based caseâ€“control study. Cancer Causes and Control, 2011, 22, 1445-1452.	1.8	23
257	Validation of exposure assessment and assessment of recruitment methods for a prospective cohort study of mobile phone users (COSMOS) in Finland: a pilot study. Environmental Health, 2011, 10, 14.	4.0	13
258	Incidence trends of pediatric inflammatory bowel disease in Finland, 1987â€“2003, a nationwide study. Inflammatory Bowel Diseases, 2011, 17, 1778-1783.	1.9	112
259	An international prospective cohort study of mobile phone users and health (Cosmos): Design considerations and enrolment. Cancer Epidemiology, 2011, 35, 37-43.	1.9	66
260	Location of Gliomas in Relation to Mobile Telephone Use: A Case-Case and Case-Specular Analysis. American Journal of Epidemiology, 2011, 174, 2-11.	3.4	38
261	Prostate Cancer Screening: A Survey of Attitudes and Practices among Finnish Physicians in 1999 and 2007. Journal of Medical Screening, 2011, 18, 46-49.	2.3	6
262	Incidence trends of vestibular schwannomas in Denmark, Finland, Norway and Sweden in 1987â€“2007. British Journal of Cancer, 2011, 105, 1069-1075.	6.4	25
263	Lens opacities among physicians occupationally exposed to ionizing radiation â€“ a pilot study in Finland. Scandinavian Journal of Work, Environment and Health, 2011, 37, 237-243.	3.4	55
264	Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infection: A Randomized, Doubleâ€Blinded Trial among Young Finnish Men. Journal of Infectious Diseases, 2010, 202, 809-814.	4.0	168
265	Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region. Breast Cancer Research and Treatment, 2010, 121, 671-678.	2.5	12
266	Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer. Breast Cancer Research and Treatment, 2010, 122, 553-566.	2.5	23
267	Cancer incidence in the vicinity of Finnish nuclear power plants: an emphasis on childhood leukemia. Cancer Causes and Control, 2010, 21, 587-595.	1.8	18
268	Exogenous sex hormone use and risk of meningioma: a population-based caseâ€“control study in Finland. Cancer Causes and Control, 2010, 21, 2149-2156.	1.8	47
269	Nocturia Frequency, Bother, and Quality of Life: How Often Is Too Often? A Population-Based Study in Finland. European Urology, 2010, 57, 488-498.	1.9	290
270	Balancing the harms and benefits of early detection of prostate cancer. Cancer, 2010, 116, 4857-4865.	4.1	37

#	Article	IF	Citations
271	Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. International Journal of Cancer, 2010, 127, 1650-1659.	5.1	88
272	Results of the three rounds of the Finnish Prostate Cancer Screening Trialâ€"The incidence of advanced cancer is decreased by screening. International Journal of Cancer, 2010, 127, 1699-1705.	5.1	11
273	False-positive screening results in the Finnish prostate cancer screening trial. British Journal of Cancer, 2010, 102, 469-474.	6.4	38
274	Why do men opt out of prostateâ€cancer screening? Attitudes and perception among participants and nonâ€participants of a screening trial. BJU International, 2010, 106, 472-477.	2.5	9
275	Radiation doses from global fallout and cancer incidence among reindeer herders and Sami in Northern Finland. Occupational and Environmental Medicine, 2010, 67, 737-743.	2.8	8
276	Response: Re: Time Trends in Brain Tumor Incidence Rates in Denmark, Finland, Norway, and Sweden, 1974â€"2003. Journal of the National Cancer Institute, 2010, 102, 742-743.	6.3	2
277	Author's Response: Response to commentary: Meningioma and mobile phone use--a collaborative case-control study in five North European countries. International Journal of Epidemiology, 2010, 39, 1119-1119.	1.9	0
278	Interaction Between 5 Genetic Variants and Allergy in Glioma Risk. American Journal of Epidemiology, 2010, 171, 1165-1173.	3.4	47
279	Prostate cancer and deprivation. BMJ: British Medical Journal, 2010, 340, c2043-c2043.	2.3	0
280	1763 ARE URINARY STORAGE SYMPTOMS RELATED WITH SMOKING? A POPULATION-BASED STUDY IN WOMEN. Journal of Urology, 2010, 183, .	0.4	0
281	971 INTERVAL CANCERS IN THE SCREENING OF PROSTATE CANCER: RESULTS FROM THE HELSINKI AREA OF THE ERSPC STUDY. European Urology Supplements, 2010, 9, 304-305.	0.1	0
282	A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta OncolÃ³gica, 2010, 49, 767-775.	1.8	66
283	Prostate cancer incidence and mortality trends in 37 European countries: An overview. European Journal of Cancer, 2010, 46, 3040-3052.	2.8	260
284	Lead-time in the European Randomised Study of Screening for Prostate Cancer. European Journal of Cancer, 2010, 46, 3102-3108.	2.8	53
285	Foreword: Meeting the challenge of prostate cancer. European Journal of Cancer, 2010, 46, 3037-3039.	2.8	2
286	Time Trends in Brain Tumor Incidence Rates in Denmark, Finland, Norway, and Sweden, 1974-2003. Journal of the National Cancer Institute, 2009, 101, 1721-1724.	6.3	121
287	Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. British Journal of Cancer, 2009, 101, 843-848.	6.4	54
288	A Systematic Evaluation of Factors Associated With Nocturiaâ€"The Population-based FINNO Study. American Journal of Epidemiology, 2009, 170, 361-368.	3.4	155

#	Article	IF	Citations
289	Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2000-2005.	2.5	10
290	Prostate Cancer Mortality Reduction by Prostate-Specific Antigenâ€"Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). European Urology, 2009, 56, 584-591.	1.9	180
291	Long-term health outcomes in pediatric inflammatory bowel disease: A population-based study. Inflammatory Bowel Diseases, 2009, 15, 56-62.	1.9	84
292	Biological aggressiveness of prostate cancer in the Finnish screening trial. International Journal of Cancer, 2009, 124, 547-552.	5.1	7
293	MNS16A minisatellite genotypes in relation to risk of glioma and meningioma and to glioblastoma outcome. International Journal of Cancer, 2009, 125, 968-972.	5.1	27
294	Mobile phone use and location of glioma: A caseâ€"case analysis. Bioelectromagnetics, 2009, 30, 176-182.	1.6	13
295	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	21.4	389
296	Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. Acta Neurologica Scandinavica, 2009, 119, 55-60.	2.1	18
297	Determinants of mobile phone output power in a multinational study: implications for exposure assessment. Occupational and Environmental Medicine, 2009, 66, 664-671.	2.8	62
298	CASP8 D302H and meningioma risk: An analysis of five case-control series. Cancer Letters, 2009, 273, 312-315.	7.2	17
299	More Study Needed on Morning Erections and Erectile Dysfunction. American Journal of Medicine, 2009, 122, e7-e8.	1.5	0
300	Quantifying the Impact of Selection Bias Caused by Nonparticipation in a Caseâ€"Control Study of Mobile Phone Use. Annals of Epidemiology, 2009, 19, 33-41.e1.	1.9	58
301	HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Research, 2009, 11, R37.	5.0	25
302	Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine, 2009, 360, 1320-1328.	27.0	3,540
303	IMPACT OF OVERACTIVE BLADDER DRY AND WET ON HEALTH-RELATED QUALITY OF LIFE: A POPULATION-BASED STUDY. Journal of Urology, 2009, 181, 86-86.	0.4	0
304	PC DETECTION IN MEN WITH INITIAL PSA LEVELS < 3.0 NG/ML. DATA FROM ERSPC 1993- 2007. Journal of Urology, 2009, 181, 646.	0.4	1
305	Indoor radon and deaths from lung cancer. BMJ: British Medical Journal, 2009, 338, a3128-a3128.	2.3	4
306	XRCC1 and XRCC3 variants and risk of glioma and meningioma. Journal of Neuro-Oncology, 2008, 88, 135-142.	2.9	77

#	Article	IF	Citations
307	Reliability and validity of a bioimpedance measurement device in the assessment of UVR damage to the skin. Archives of Dermatological Research, 2008, 300, 253-261.	1.9	4
308	Assessment of causes of death in a prostate cancer screening trial. International Journal of Cancer, 2008, 122, 413-417.	5.1	47
309	Reducing overestimation in reported mobile phone use associated with epidemiological studies. Bioelectromagnetics, 2008, 29, 559-563.	1.6	27
310	Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland. American Journal of Obstetrics and Gynecology, 2008, 199, 153.e1-153.e12.	1.3	34
311	Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study. Acta Neurologica Scandinavica, 2008, 117, 332-336.	2.1	3
312	Is the incidence of meningiomas underestimated? A regional survey. British Journal of Cancer, 2008, 99, 182-184.	6.4	43
313	Increased longâ€term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clinical Endocrinology, 2008, 68, 450-457.	2.4	47
314	Diagnostic Value of Free Prostate-Specific Antigen among Men with a Prostate-Specific Antigen Level of <3.0Î¼g per Liter. European Urology, 2008, 54, 362-370.	1.9	40
315	Asbestos-related pleural and lung fibrosis in patients with retroperitoneal fibrosis. Orphanet Journal of Rare Diseases, 2008, 3, 29.	2.7	11
316	Ionizing Radiation and Risk of Chronic Lymphocytic Leukemia in the 15-Country Study of Nuclear Industry Workers. Radiation Research, 2008, 170, 661-665.	1.5	34
317	Regular Intercourse Protects Against Erectile Dysfunction: Tampere Aging Male Urologic Study. American Journal of Medicine, 2008, 121, 592-596.	1.5	44
318	Seizure-freedom with combination therapy in localization-related epilepsy. Seizure: the Journal of the British Epilepsy Association, 2008, 17, 276-280.	2.0	13
319	Onset, prognosis and risk factors for widespread pain in schoolchildren: A prospective 4-year follow-up study. Pain, 2008, 138, 681-687.	4.2	100
320	Early detection of skin cancer as public health policy: Comparison of campaign and routine activity. Preventive Medicine, 2008, 46, 160-165.	3.4	1
321	Cancer screening: Evidence and practice in Europe 2008. European Journal of Cancer, 2008, 44, 1404-1413.	2.8	100
322	MAJOR RISK FACTORS FOR NOCTURIA IN A POPULATION- BASED STUDY. Journal of Urology, 2008, 179, 540-541.	0.4	0
323	Depressive Symptoms Increase the Incidence of Nocturia: Tampere Aging Male Urologic Study (TAMUS). Journal of Urology, 2008, 179, 1897-1901.	0.4	52
324	INCIDENCE OF ADVANCED PROSTATE CANCER IN THE FINNISH PROSTATE CANCER SCREENING TRIAL. Journal of Urology, 2008, 179, 598-598.	0.4	0

#	Article	IF	Citations
325	The Effects of Lifestyle Factors on the Incidence of Nocturia. Journal of Urology, 2008, 180, 2059-2062.	0.4	40
326	BOTHER AND IMPACT OF NOCTURIA ON HEALTH-RELATED QUALITY OF LIFE. Journal of Urology, 2008, 179, 112-112.	0.4	0
327	Reproductive Factors and Risk of Meningioma and Glioma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2663-2670.	2.5	81
328	Functional Polymorphisms in Folate Metabolism Genes Influence the Risk of Meningioma and Glioma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1195-1202.	2.5	48
329	Comprehensive Analysis of DNA Repair Gene Variants and Risk of Meningioma. Journal of the National Cancer Institute, 2008, 100, 270-276.	6.3	56
330	The Common D302H Variant of CASP8 Is Associated with Risk of Glioma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 987-989.	2.5	45
331	Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. Human Molecular Genetics, 2008, 17, 800-805.	2.9	67
332	Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study. American Journal of Epidemiology, 2008, 168, 925-931.	3.4	100
333	Meningioma and mobile phone use--a collaborative case-control study in five North European countries. International Journal of Epidemiology, 2008, 37, 1304-1313.	1.9	59
334	An International Case-Control Study of Interleukin-4RÎ±, Interleukin-13, and Cyclooxygenase-2 Polymorphisms and Glioblastoma Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2448-2454.	2.5	55
335	Cardiovascular drug use and the incidence of erectile dysfunction. International Journal of Impotence Research, 2007, 19, 208-212.	1.8	44
336	Incidence of gliomas by anatomic location. Neuro-Oncology, 2007, 9, 319-325.	1.2	250
337	An International Case-Control Study of Glutathione Transferase and Functionally Related Polymorphisms and Risk of Primary Adult Brain Tumors. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 559-565.	2.5	56
338	Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother. International Journal of Impotence Research, 2007, 19, 317-320.	1.8	24
339	Increased Cardiovascular and Cancer Mortality after Radioiodine Treatment for Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2190-2196.	3.6	132
340	Mortality from diseases other than cancer following low doses of ionizing radiation: results from the 15-Country Study of nuclear industry workers. International Journal of Epidemiology, 2007, 36, 1126-1135.	1.9	135
341	Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries. Journal of the National Cancer Institute, 2007, 99, 1881-1887.	6.3	157
342	Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2226-2232.	2.5	166

#	Article	IF	Citations
343	Allergic Conditions and Brain Tumor Risk. American Journal of Epidemiology, 2007, 166, 941-950.	3.4	106
344	Sensitivity in cancer screening. Journal of Medical Screening, 2007, 14, 174-177.	2.3	57
345	An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. American Journal of Clinical Nutrition, 2007, 86, 714-717.	4.7	354
346	Estimating the Cosmic Radiation Dose for a Cabin Crew With Flight Timetables. Journal of Occupational and Environmental Medicine, 2007, 49, 540-545.	1.7	12
347	Prostate cancer risk among users of finasteride and alpha-blockers â€“ A population based caseâ€“control study. European Journal of Cancer, 2007, 43, 775-781.	2.8	11
348	The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Design, Epidemiological Methods and Descriptive Results. Radiation Research, 2007, 167, 361-379.	1.5	125
349	The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Estimates of Radiation-Related Cancer Risks. Radiation Research, 2007, 167, 396-416.	1.5	1,139
350	Bidirectional Relationship Between Depression and Erectile Dysfunction. Journal of Urology, 2007, 177, 669-673.	0.4	104
351	Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland. PLoS ONE, 2007, 2, e195.	2.5	61
352	Medical history, cigarette smoking and risk of acoustic neuroma: An international case-control study. International Journal of Cancer, 2007, 120, 103-110.	5.1	34
353	Mobile phone use and risk of glioma in 5 North European countries. International Journal of Cancer, 2007, 120, 1769-1775.	5.1	148
354	Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer, 2007, 109, 1972-1979.	4.1	120
355	Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. British Journal of Cancer, 2007, 96, 56-60.	6.4	19
356	Angiosarcoma after radiotherapy: a cohort study of 332â€‰163 Finnish cancer patients. British Journal of Cancer, 2007, 97, 115-117.	6.4	76
357	Risk factors for development of non-specific musculoskeletal pain in preteens and early adolescents: a prospective 1-year follow-up study. BMC Musculoskeletal Disorders, 2007, 8, 46.	1.9	100
358	Impact of LUTS Using Bother Index in DAN-PSS-1 Questionnaire. European Urology, 2007, 51, 473-478.	1.9	27
359	KLF6 IVS1 -27G>A Variant and the Risk of Prostate Cancer in Finland. European Urology, 2007, 52, 1076-1081.	1.9	14
360	Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. Journal of Neuro-Oncology, 2007, 82, 229-237.	2.9	55

#	Article	IF	Citations
361	The INTERPHONE study: design, epidemiological methods, and description of the study population. European Journal of Epidemiology, 2007, 22, 647-664.	5.7	225
362	462: Antidiabetic Medication and Prostate Cancer Risk - A Population-Based Case-Control Study. Journal of Urology, 2007, 177, 155-155.	0.4	0
363	69: Prevalence of Overactive Bladder is Overestimated. Journal of Urology, 2007, 177, 24-24.	0.4	0
364	1719: Statins and Prostate Cancer Among Men Participating in the Finnish Prostate Cancer Screening Trial. Journal of Urology, 2007, 177, 572-572.	0.4	1
365	Effect of Nonsteroidal Anti-Inflammatory Drug Use on the Incidence of Erectile Dysfunction. Journal of Urology, 2006, 175, 1812-1816.	0.4	51
366	Is Nocturia Equally Common Among Men and Women? A Population Based Study in Finland. Journal of Urology, 2006, 175, 596-600.	0.4	128
367	Incidence of Nocturia in 50 to 80-Year-Old Finnish Men. Journal of Urology, 2006, 176, 2541-2545.	0.4	43
368	Population exposure to ultraviolet radiation in Finland 1920â€“1995: Exposure trends and a time-series analysis of exposure and cutaneous melanoma incidence. Environmental Research, 2006, 101, 123-131.	7.5	25
369	Well water radioactivity and risk of cancers of the urinary organs. Environmental Research, 2006, 102, 333-338.	7.5	63
370	No increase in thyroid cancer among children and adolescents in Finland due to Chernobyl accident. European Journal of Cancer, 2006, 42, 1167-1171.	2.8	16
371	Smoking causes erectile dysfunction through vascular disease. Urology, 2006, 68, 1318-1322.	1.0	13
372	Antiepileptic drug use and birth rate in patients with epilepsy--a population-based cohort study in Finland. Human Reproduction, 2006, 21, 2290-2295.	0.9	36
373	Epidemiological risk assessment of mobile phones and cancer: where can we improve?. European Journal of Cancer Prevention, 2006, 15, 516-523.	1.3	22
374	Reply: Mobile phone use and acoustic neuroma in five North European countries. British Journal of Cancer, 2006, 94, 1352-1353.	6.4	3
375	Vitamin D fortification as public health policy: significant improvement in vitamin D status in young Finnish men. European Journal of Clinical Nutrition, 2006, 60, 1035-1038.	2.9	88
376	Incidence of inflammatory bowel disease in finnish children, 1987â€“2003. Inflammatory Bowel Diseases, 2006, 12, 677-683.	1.9	152
377	Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. Journal of Neuro-Oncology, 2006, 80, 1-7.	2.9	116
378	Kidney Toxicity of Ingested Uranium From Drinking Water. American Journal of Kidney Diseases, 2006, 47, 972-982.	1.9	165

#	Article	IF	Citations
379	Risk factors for traumatic and non-traumatic lower limb pain among preadolescents: a population-based study of Finnish schoolchildren. BMC Musculoskeletal Disorders, 2006, 7, 3.	1.9	30
380	Incidence of bone and soft tissue sarcoma after radiotherapy: A cohort study of 295,712 Finnish cancer patients. International Journal of Cancer, 2006, 118, 1017-1021.	5.1	73
381	Cancer risk among chernobyl cleanup workers in Estonia and Latvia, 1986â€“1998. International Journal of Cancer, 2006, 119, 162-168.	5.1	41
382	Nocturia and Obesity: A Population-based Study in Finland. American Journal of Epidemiology, 2006, 163, 1003-1011.	3.4	60
383	Validation of short term recall of mobile phone use for the Interphone study. Occupational and Environmental Medicine, 2006, 63, 237-243.	2.8	124
384	Congenital structural anomalies in offspring of women with epilepsyâ€”a population-based cohort study in Finland. International Journal of Epidemiology, 2006, 35, 280-287.	1.9	42
385	Epidemiologic Assessment of Cancer Risk from Mobile Phone Use: Where are We. Progress in Electromagnetics Research Symposium: [proceedings] Progress in Electromagnetics Research Symposium, 2006, 2, 197-199.	0.4	1
386	Cancer incidence among physicians occupationally exposed to ionizing radiation in Finland. Scandinavian Journal of Work, Environment and Health, 2006, 32, 368-373.	3.4	21
387	Meta-analysis of mobile phone use and intracranial tumors. Scandinavian Journal of Work, Environment and Health, 2006, 32, 171-177.	3.4	50
388	URINE, HAIR, AND NAILS AS INDICATORS FOR INGESTION OF URANIUM IN DRINKING WATER. Health Physics, 2005, 88, 229-242.	0.5	75
389	Mobile phone use and risk of acoustic neuroma: results of the Interphone caseâ€“control study in five North European countries. British Journal of Cancer, 2005, 93, 842-848.	6.4	181
390	Relationship between smoking and erectile dysfunction. International Journal of Impotence Research, 2005, 17, 164-169.	1.8	22
391	Association between the Bothersomeness of Lower Urinary Tract Symptoms and the Prevalence of Erectile Dysfunction. Journal of Sexual Medicine, 2005, 2, 438-444.	0.6	26
392	Radon and other natural radionuclides in drinking water and risk of stomach cancer: A case-cohort study in Finland. International Journal of Cancer, 2005, 114, 109-113.	5.1	77
393	Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997. International Journal of Cancer, 2005, 117, 996-1001.	5.1	104
394	Validity and reliability of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus: Comment on the article by Kozora et al. Arthritis and Rheumatism, 2005, 53, 478-479.	6.7	1
395	Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology, 2005, 64, 1874-1878.	1.1	272
396	Bone as a Possible Target of Chemical Toxicity of Natural Uranium in Drinking Water. Environmental Health Perspectives, 2005, 113, 68-72.	6.0	206

#	Article	IF	Citations
397	Treatment delay and the risk of prolonged status epilepticus. Neurology, 2005, 65, 1316-1318.	1.1	139
398	Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ: British Medical Journal, 2005, 330, 223.	2.3	1,284
399	Lower Limb Pain in a Preadolescent Population: Prognosis and Risk Factors for Chronicity--A Prospective 1- and 4-Year Follow-up Study. Pediatrics, 2005, 116, 673-681.	2.1	65
400	Breast cancer risk among Finnish cabin attendants: a nested case-control study. Occupational and Environmental Medicine, 2005, 62, 488-493.	2.8	63
401	PREVALENCE OF CLINICALLY CONFIRMED INTERSTITIAL CYSTITIS IN WOMEN: A POPULATION BASED STUDY IN FINLAND. Journal of Urology, 2005, 174, 581-583.	0.4	89
402	EFFECT OF LOWER URINARY TRACT SYMPTOMS ON THE INCIDENCE OF ERECTILE DYSFUNCTION. Journal of Urology, 2005, 174, 205-209.	0.4	43
403	Serum IgA, IgG, and IgM concentrations in patients with epilepsy and matched controls: a cohort-based cross-sectional study. Epilepsy and Behavior, 2005, 6, 191-195.	1.7	24
404	Celiac disease-related antibodies in an epilepsy cohort and matched reference population. Epilepsy and Behavior, 2005, 6, 388-392.	1.7	37
405	Antimitochondrial antibodies in patients with epilepsy. Epilepsy and Behavior, 2005, 7, 95-97.	1.7	12
406	Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 72-74.	2.0	13
407	Selection Bias Due to Differential Participation in a Caseâ€“Control Study of Mobile Phone Use and Brain Tumors. Annals of Epidemiology, 2005, 15, 321-325.	1.9	50
408	Changes in prevalence of urinary symptoms in Finnish men. Scandinavian Journal of Urology and Nephrology, 2004, 38, 378-384.	1.4	16
409	Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial. Clinical Cancer Research, 2004, 10, 2231-2236.	7.0	39
410	Birth Rate among Patients with Epilepsy: A Nationwide Population-based Cohort Study in Finland. American Journal of Epidemiology, 2004, 159, 1057-1063.	3.4	67
411	A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen. BJU International, 2004, 93, 52-56.	2.5	80
412	Effect of life-style factors on incidence of erectile dysfunction. International Journal of Impotence Research, 2004, 16, 389-394.	1.8	77
413	Effects of Age, Comorbidity and Lifestyle Factors on Erectile Function: Tampere Ageing Male Urological Study (TAMUS). European Urology, 2004, 45, 628-633.	1.9	44
414	Cosmic radiation and cancer mortality among airline pilots: results from a European cohort study (ESCAPE). Radiation and Environmental Biophysics, 2004, 42, 247-256.	1.4	76

#	Article	IF	Citations
415	CHEK2 1100delC is not a risk factor for male breast cancer population. International Journal of Cancer, 2004, 108, 475-476.	5.1	55
416	Incidence trends of adult primary intracerebral tumors in four Nordic countries. International Journal of Cancer, 2004, 108, 450-455.	5.1	108
417	Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-postitive PSA results in prostate cancer screening. International Journal of Cancer, 2004, 111, 310-315.	5.1	66
418	Frequent amplification and overexpression of CCND1 in male breast cancer. International Journal of Cancer, 2004, 111, 968-971.	5.1	26
419	Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. International Journal of Cancer, 2004, 111, 940-943.	5.1	23
420	Anticardiolipin and antinuclear antibodies in epilepsyâ€"a population-based cross-sectional study. Epilepsy Research, 2004, 58, 13-18.	1.6	41
421	BRCA2 Mutations in 154 Finnish Male Breast Cancer Patients. Neoplasia, 2004, 6, 541-545.	5.3	33
422	Prognosis of non-specific musculoskeletal pain in preadolescents: A prospective 4-year follow-up study till adolescence. Pain, 2004, 110, 550-559.	4.2	188
423	Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet, The, 2004, 363, 1422-1426.	13.7	162
424	Occupational radiation dose estimation for Finnish aircraft cabin attendants. Scandinavian Journal of Work, Environment and Health, 2004, 30, 157-163.	3.4	10
425	1790: Determining Cause of Death in Prostate Cancer Screening. Journal of Urology, 2004, 171, 473-473.	0.4	0
426	Androgen Receptor Gene Alterations in Finnish Male Breast Cancer. Breast Cancer Research and Treatment, 2003, 77, 167-170.	2.5	34
427	Mortality from cancer and other causes among male airline cockpit crew in Europe. International Journal of Cancer, 2003, 106, 946-952.	5.1	99
428	The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?. BJU International, 2003, 92, 14-16.	2.5	9
429	Prevalence and Severity of Erectile Dysfunction in 50 to 75-Year-Old Finnish Men. Journal of Urology, 2003, 170, 2342-2344.	0.4	50
430	Effect of chronic diseases on incidence of erectile dysfunction. Urology, 2003, 62, 1097-1102.	1.0	41
431	Interstitial cystitisâ€"like urinary symptoms among patients with SjÃ¶grenâ€™s syndrome: a population-based study in Finland. American Journal of Medicine, 2003, 115, 62-65.	1.5	117
432	Geographical differences in the prevalence of hypospadias in Finland. Environmental Research, 2003, 92, 118-123.	7.5	14

#	Article	IF	Citations
433	Cognitive Impairment in Systemic Lupus Erythematosus and Neuropsychiatric Systemic Lupus Erythematosus: A Population-Based Neuropsychological Study. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 145-151.	1.3	62
434	Reliability and Validity of Prostate-Specific Antigen. JAMA - Journal of the American Medical Association, 2003, 290, 1705.	7.4	1
435	Mortality from Cancer and Other Causes among Airline Cabin Attendants in Europe: A Collaborative Cohort Study in Eight Countries. American Journal of Epidemiology, 2003, 158, 35-46.	3.4	88
436	Hereditary Minisatellite Mutations among the Offspring of Estonian Chernobyl Cleanup Workers. Radiation Research, 2003, 159, 651-655.	1.5	48
437	Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen. Clinical Cancer Research, 2003, 9, 2435-9.	7.0	21
438	Cancer incidence among 10,211 airline pilots: a Nordic study. Aviation, Space, and Environmental Medicine, 2003, 74, 699-706.	0.5	44
439	Incidence of cancer among Nordic airline pilots over five decades: occupational cohort study. BMJ: British Medical Journal, 2002, 325, 567-567.	2.3	129
440	Brain Tumors and Salivary Gland Cancers Among Cellular Telephone Users. Epidemiology, 2002, 13, 356-359.	2.7	212
441	Family History and Prostate Cancer Screening With Prostate-Specific Antigen. Journal of Clinical Oncology, 2002, 20, 2658-2663.	1.6	41
442	Risk of Subsequent Cancer Following Breast Cancer in Men. Journal of the National Cancer Institute, 2002, 94, 1330-1332.	6.3	88
443	Cancer Incidence Among Finnish Nuclear Reactor Workers. Journal of Occupational and Environmental Medicine, 2002, 44, 634-638.	1.7	13
444	Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology, 2002, 60, 846-850.	1.0	71
445	Prevalence of Symptoms Related to Interstitial Cystitis in Women: A Population Based Study in Finland. Journal of Urology, 2002, 168, 139-143.	0.4	119
446	Renal effects of uranium in drinking water.. Environmental Health Perspectives, 2002, 110, 337-342.	6.0	345
447	Estimation of Prostate Cancer Risk on the Basis of Total and Free Prostate-Specific Antigen, Prostate Volume and Digital Rectal Examination. European Urology, 2002, 41, 619-627.	1.9	44
448	Largeâ€scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. International Journal of Cancer, 2002, 97, 237-244.	5.1	247
449	Should we start population screening for prostate cancer? Randomised trials are still needed. International Journal of Cancer, 2002, 97, 377-378.	5.1	16
450	Haemophilus influenzae type b vaccine formulation and risk of childhood leukaemia. British Journal of Cancer, 2002, 87, 511-512.	6.4	11

#	Article	IF	Citations
451	Lead-time in prostate cancer screening (Finland). Cancer Causes and Control, 2002, 13, 279-285.	1.8	53
452	Uranium and other natural radionuclides in drinking water and risk of leukemia: a case-cohort study in Finland. Cancer Causes and Control, 2002, 13, 825-829.	1.8	53
453	PREDICTORS OF BIOLOGICAL AGGRESSIVENESS OF PROSTATE SPECIFIC ANTIGEN SCREENING DETECTED PROSTATE CANCER. Journal of Urology, 2001, 165, 1569-1574.	0.4	9
454	Prostate cancer screening. Lancet, The, 2001, 357, 1201.	13.7	1
455	Randomized Screening Trial for Prostate Cancer in Finland. European Urology, 2001, 39, 32-32.	1.9	5
456	A randomized trial of the choice of treatment in prostate cancer: design and baseline characteristics. BJU International, 2001, 88, 708-715.	2.5	24
457	Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a populationâ€based evaluation. Arthritis and Rheumatism, 2001, 45, 419-423.	6.7	277
458	Mortality after Cerebral Angiography with or without Radioactive Thorotrast: An International Cohort of 3,143 Two-Year Survivors. Radiation Research, 2001, 156, 136-150.	1.5	22
459	Three-Year Results of the Finnish Prostate Cancer Screening Trial. Journal of the National Cancer Institute, 2001, 93, 552-553.	6.3	39
460	Epidemiologic Studies Of Pilots And Aircrew. Health Physics, 2000, 79, 576-584.	0.5	58
461	Haemophilus influenzae type B vaccination and risk of childhood leukaemia in a vaccine trial in Finland. British Journal of Cancer, 2000, 83, 956-958.	6.4	31
462	Extremely Low-Frequency Magnetic Fields and Childhood Acute Lymphoblastic Leukemia: An Exploratory Analysis of Alternative Exposure Metrics. American Journal of Epidemiology, 2000, 152, 20-31.	3.4	32
463	Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. American Journal of Medicine, 2000, 109, 712-717.	1.5	83
464	Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology, 2000, 56, 418-422.	1.0	141
465	USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND Î±1-PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCER. Journal of Urology, 2000, 164, 1956-1960.	0.4	26
466	Do Confounding or Selection Factors of Residential Wiring Codes and Magnetic Fields Distort Findings of Electromagnetic Fields Studies?. Epidemiology, 2000, 11, 189-198.	2.7	64
467	USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND ??1-PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCER. Journal of Urology, 2000, , 1956-1960.	0.4	2
468	Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2744-2747.	3.6	63

#	Article	IF	Citations
469	Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland.. Environmental Health Perspectives, 1999, 107, 705-710.	6.0	236
470	European randomized study of prostate cancer screening: first-year results of the Finnish trial. British Journal of Cancer, 1999, 79, 1210-1214.	6.4	73
471	Cancer risk following radiotherapy for infertility or menstrual disorders. , 1999, 82, 795-798.		10
472	Rationale for randomised trials of prostate cancer screening. European Journal of Cancer, 1999, 35, 262-271.	2.8	58
473	Temporal and Other Exposure Aspects of Residential Magnetic Fields Measurement in Relation to Acute Lymphoblastic Leukaemia in Children: The National Cancer Institute Children's Cancer Group Study. Radiation Protection Dosimetry, 1999, 83, 53-60.	0.8	4
474	Do Recorded Doses Overestimate True Doses Received by Chernobyl Cleanup Workers? Results of Cytogenetic Analyses of Estonian Workers by Fluorescence In Situ Hybridization. Radiation Research, 1998, 150, 237.	1.5	48
475	Measuring social class differences in cancer patient survival: is it necessary to control for social class differences in general population mortality? A Finnish population-based study. Journal of Epidemiology and Community Health, 1998, 52, 727-734.	3.7	57
476	Hysterectomy and subsequent risk of cancer. International Journal of Epidemiology, 1997, 26, 476-483.	1.9	29
477	Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. British Journal of Cancer, 1997, 75, 301-305.	6.4	120
478	Biodosimetry of Chernobyl Cleanup Workers from Estonia and Latvia Using the Glycophorin A In Vivo Somatic Cell Mutation Assay. Radiation Research, 1997, 147, 215.	1.5	35
479	Thyroid Nodularity and Cancer among Chernobyl Cleanup Workers from Estonia. Radiation Research, 1997, 147, 225.	1.5	46
480	The Estonian Study of Chernobyl Cleanup Workers: I. Design and Questionnaire Data. Radiation Research, 1997, 147, 641.	1.5	19
481	The Estonian Study of Chernobyl Cleanup Workers: II. Incidence of Cancer and Mortality. Radiation Research, 1997, 147, 653.	1.5	55
482	Lung cancer risk from indoor radon. Lancet, The, 1996, 348, 1662-1663.	13.7	2
483	Retrospective dose estimates in Estonian Chernobyl clean-up workers by means of FISH. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1996, 369, 7-12.	1.2	21
484	Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. British Journal of Cancer, 1996, 74, 568-572.	6.4	27
485	Prevalence of symptoms among patients with advanced cancer: An international collaborative study. Journal of Pain and Symptom Management, 1996, 12, 3-10.	1.2	423
486	Breast self-examination and survival from breast cancer. Breast Cancer Research and Treatment, 1996, 38, 161-168.	2.5	26

#	Article	IF	Citations
487	Cancer consequences of the Chernobyl accident in Europe outside the former USSR: A review. , 1996, 67, 343-352.		42
488	Indoor Radon Exposure and Risk of Lung Cancer: a Nested Case--Control Study in Finland. Journal of the National Cancer Institute, 1996, 88, 966-972.	6.3	111
489	Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening. Journal of Medical Screening, 1996, 3, 97-104.	2.3	98
490	Glycophorin A biodosimetry in Chernobyl cleanup workers from the Baltic countries. BMJ: British Medical Journal, 1996, 312, 1078-1079.	2.3	26
491	Social Class and Cancer Patient Survival in Finland. American Journal of Epidemiology, 1995, 142, 1089-1102.	3.4	73
492	Incidence of cancer among Finnish airline cabin attendants, 1967-92. BMJ: British Medical Journal, 1995, 311, 649-652.	2.3	189
493	Overexpression of p53 and long-term survival in colon carcinoma. British Journal of Cancer, 1994, 70, 293-296.	6.4	74
494	Colon Cancer Survival in Finland. Cancer, 1993, 71, 2884-2885.	4.1	0
495	Social class and colon cancer survival in finland. Cancer, 1992, 70, 402-409.	4.1	54
496	The effect of breast self-examination on breast cancer survival. Patient Education and Counseling, 1991, 18, 279.	2.2	0